158. Clin Cancer Res. 2018 Jul 30. pii: clincanres.0585.2018. doi:10.1158/1078-0432.CCR-18-0585. [Epub ahead of print]Pathological response and survival in triple-negative breast cancer followingneoadjuvant carboplatin plus docetaxel.Sharma P(1), López-Tarruella S(2), Garcia-Saenz JA(3), Khan QJ(4), Gomez H(5),Prat A(6), Moreno F(7), Jerez-Gilarranz Y(8), Barnadas A(9), Picornell AC(10),Del Monte-Millán M(11), Gonzalez-Rivera M(12), Massarrah T(13), Pelaez-LorenzoB(14), Palomero MI(13), González Del Val R(13), Cortes J(15), Fuentes RiveraH(16), Bretel Morales D(16), Marquez-Rodas I(17), Perou CM(18), Lehn C(19), Wang YY(19), Klemp JR(19), Mammen JM(20), Wagner J(20), Amin A(20), O'Dea AP(19),Heldstab J(21), Jensen RA(22), Kimler BF(23), Godwin AK(24), Martín M(25).Author information: (1)Medical Oncology, University of Kansas Medical Center psharma2@kumc.edu.(2)Medical Oncology, Hospital General Universitario Gregorio Marañón, Institutode Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense,CiberOnc, GEICAM.(3)Medical Oncology, IdISSC. CIBERONC. Hospital Clinico San Carlos.(4)Inernal Medicine, University of Kansas Medical Center.(5)Instituto Nacional de Enfermedades Neoplasicas.(6)Department of Medical Oncology, Hospital Clinic de Barcelona.(7)Oncology Unit, Hospital Clínico Universitario San Carlos.(8)Hospital General Universitario Gregorio Marañón. Instituto de InvestigaciónSanitaria Gregorio Marañón (IiSGM), Hospital General Universitario GregorioMarañón, Madrid.(9)Department of Medical Oncology, Hospital Santa Creu i Sant Pau.(10)Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañon(IiSGM).(11)Medical Oncology Service, H.G.U. Gregorio Marañón, Instituto de InvestigaciónBiomédica Hospital Gregorio Marañón. CiberOnc.(12)Laboratory of Translational Oncology, Instituto de Investigación SanitariaGregorio Marañón, Madrid.(13)Medical Oncology Service, Hospital General Universitario Gregorio Marañón,Madrid.(14)Oncology, Hospital Clínico, Valladolid.(15)Medical Oncology, Ramon y Cajal University Hospital.(16)Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas.(17)Oncologia, Hospital General Universitario Gregorio Maranon (HGUGM).(18)Genetics, University of North Carolina School of Medicine.(19)Internal Medicine, University of Kansas Medical Center.(20)Surgery, University of Kansas Medical Center.(21)Medical Oncology, University of Kansas Medical Center.(22)Pathology and Laboratory Medicine, University of Kansas Medical Center.(23)Radiation Oncology, University of Kansas Medical Center.(24)Department of Pathology and Laboratory Medicine, University of Kansas MedicalCenter.(25)Medical Oncology, Hospital Gregorio Marañón.PURPOSE: Prognostic value of pCR and extent of pathological response attainedwith anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) inTNBC is unknown. We report recurrence-free survival (RFS) and overall survival(OS) according to degree of pathological response in patients treated withcarboplatin (Cb) plus docetaxel (D) NAC.EXPERIMENTAL DESIGN: 190 patients with stage I-III TNBC were treated withneoadjuvant Cb(AUC6) plus D(75mg/m2) every 21 days x 6 cycles. pCR (no evidenceof invasive tumor in breast and axilla) and Residual Cancer Burden (RCB) wereevaluated. Patients were followed for recurrence and survival. Extent ofpathological response was associated with RFS and OS using the Kaplan-Meiermethod.RESULTS: Median age was 51 years, and 52% were node-positive. pCR and RCB I rateswere 55% and 13%, respectively. 5% of pCR patients, 0% of RCB I patients, and 58%of RCB II/III patients received adjuvant anthracyclines. Three-year RFS and OSwere 79% and 87%, respectively. Three-year RFS was 90% in patients with pCR and66% in those without pCR (HR=0.30; 95% CI: 0.14-0.62, P=0.0001). 3-year OS was94% in patients with pCR and 79% in those without pCR (HR=0.25; 95% CI:0.10-0.63, P=0.001). Patients with RCB I demonstrated 3-year RFS (93%) and OS(100%) similar to those with pCR. On multivariable analysis, higher tumor stage, node positivity, and RCB II/III were associated with worse RFS.CONCLUSIONS: Neoadjuvant CbD yields encouraging efficacy in TNBC. Patientsachieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.Copyright ©2018, American Association for Cancer Research.DOI: 10.1158/1078-0432.CCR-18-0585 PMID: 30061361 